EIG121L Inhibitors
EIG121L inhibitors encompass a diverse group of chemical compounds that indirectly decrease the functional activity of EIG121L through various cellular signaling pathways. For example, Rapamycin targets the mTOR pathway, a central hub for cell growth and proliferation signals, which could indirectly lead to decreased activity of EIG121L if it is functionally downstream of mTOR. Similarly, LY294002 and Wortmannin are inhibitors of PI3K, a key player in the AKT/mTOR signaling cascade, potentially reducing EIG121L function through this mechanism. MEK inhibitors like PD98059 and U0126 disrupt the MAPK/ERK pathway, which could also result in reduced EIG121L activity if it relies on signals from ERK. SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, would lead to the downregulation of EIG121L if its activity is modulated by stress-activated pathways.
Additionally, a range of tyrosine kinase inhibitors, including Erlotinib, Sorafenib, Sunitinib, Gefitinib, and Lapatinib, act on various receptors and kinases such as EGFR, PDGFR, VEGFR, RAF, MEK, and ERK. These inhibitors have the potential to decrease the activity of EIG121L by disrupting the signal transduction processes that may govern its function. Erlotinib and Gefitinib, for instance, specifically target EGFR tyrosine kinase, and if EIG121L is regulated by EGFR signaling, its activity would be diminished by these inhibitors. Sorafenib's effect on the RAF/MEK/ERK pathway and Sunitinib's broad receptor tyrosine kinase inhibition indicate that if EIG121L is influenced by signals stemming from these pathways, its activity would be inhibited. Lapatinib's dual inhibition of EGFR and HER2 provides another avenue by which EIG121L could be indirectly suppressed if it is associated with signaling pathways initiated by these receptors. The collective action of these inhibitors on their respective targets illustrates a network of regulatory pathways that can converge on the functional modulation of EIG121L, highlighting the intricate interplay of cellular signaling in controlling protein activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, which leads to a decrease in the phosphorylation of S6K1, ultimately reducing the translation of certain mRNAs. Since mTOR signaling is crucial for many proteins' synthesis and function, inhibition by Rapamycin can lead to decreased functional activity of EIG121L if it is downstream of mTOR signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that prevents the phosphorylation and activation of AKT/PKB, downstream of which mTOR complex is a critical effector. Inhibition of this pathway would suppress mTOR activity, which may indirectly affect the stability or expression of EIG121L if it is mTOR-dependent. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which prevents the activation of the MAPK/ERK pathway. If EIG121L is regulated by ERK signaling, inhibition of this pathway by PD98059 would reduce EIG121L activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which can block the signaling pathway involved in cellular stress responses. If EIG121L is regulated or modified by p38 MAPK, its functional activity would be decreased upon inhibition with SB203580. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 also inhibits MEK, thus preventing the activation of ERK. If EIG121L is ERK-dependent, U0126-mediated inhibition of MEK would lead to decreased EIG121L activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor. By inhibiting PI3K, it blocks AKT signaling and consequently can inhibit mTOR activation. If EIG121L activity requires mTOR signaling, Wortmannin would lead to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathway. If EIG121L function is modulated through JNK signaling, its activity would be decreased by the inhibition of this pathway with SP600125. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the tyrosine kinase activity of EGFR. If EIG121L activity is regulated by signals downstream of EGFR, inhibition by Erlotinib will result in decreased functional activity of EIG121L. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets the RAF/MEK/ERK pathway. Inhibition of this pathway could result in reduced activity of EIG121L if it is regulated by this signaling cascade. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which may impair several signaling pathways, including those mediated by PDGFR and VEGFR. If EIG121L is influenced by these pathways, Sunitinib would indirectly inhibit its functional activity. | ||||||